Der kan være have behov for dosisjustering inden for det anbefalede 14+ / - 2- dages doseringsskema i vedligeholdelsesfasen (op til hver 12. dag).
PNH patients receiving Soliris therapy should be similarly monitored for intravascular haemolysis by measuring LDH levels, and may require dose adjustment within the recommended 14±2 day dosing schedule during the maintenance phase (up to every 12 days).